Erratum: Thioredoxin glutathione reductase from Schistosoma mansoni: An essential parasite enzyme and a key drug target (PLoS Medicine (2007) 4, 6, (e206) DOI:10.1371/journal.pmed.0040206);Thioredoxin glutathione reductase from Schistosoma mansoni: An essential parasite enzyme and a key drug target

PLoS Medicine

Volumn 4, Issue 6, 2007, Pages 1071-1086

  Kuntz, Angela N ^a   Davioud Charvet, Elisabeth ^b,c   Sayed, Ahmed A ^a   Califf, Lindsay L ^a   Dessolin, Jean ^b,d   Arnér, Elias S J ^e   Williams, David L ^a  

^a ILLINOIS STATE UNIVERSITY   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c CNRS   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AURANOFIN; GLUTATHIONE REDUCTASE; RNA; THIOREDOXIN REDUCTASE; ANTISCHISTOSOMAL AGENT; MULTIENZYME COMPLEX; NAPHTHAZARIN; NAPHTHOQUINONE; OXIDOREDUCTASE; RECOMBINANT PROTEIN; THIOREDOXIN GLUTATHIONE REDUCTASE;

ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; FEMALE; GENE SILENCING; IN VITRO STUDY; MOUSE; NONHUMAN; PARASITE SURVIVAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SCHISTOSOMA MANSONI; WORM INFECTION; ANIMAL; C57BL MOUSE; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; ENZYMOLOGY; GENETICS; GROWTH, DEVELOPMENT AND AGING; KINETICS; MALE; METABOLISM; OXIDATION REDUCTION REACTION; PARASITOLOGY; SCHISTOSOMIASIS MANSONI; SIGNAL TRANSDUCTION;

ANIMALS; AURANOFIN; DRUG DESIGN; FEMALE; KINETICS; MALE; MICE; MICE, INBRED C57BL; MULTIENZYME COMPLEXES; NADH, NADPH OXIDOREDUCTASES; NAPHTHOQUINONES; OXIDATION-REDUCTION; RECOMBINANT PROTEINS; RNA INTERFERENCE; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SCHISTOSOMICIDES; SIGNAL TRANSDUCTION;

EID: 34347264532     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0040264     Document Type: Erratum

References (72)

1. King CH, Dickman K, Tisch DJ (2005) Reassessment of the cost of chronic helmintic infection: A meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 365: 1561-1569.
2. Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Ehrlich Sachs S, et al. (2006) Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria: A comprehensive pro-poor health policy and strategy for the developing world. PLoS Med 3: e102. doi:10.1371/journal.pmed.0030102
3. Utzinger J, Keiser J, Shuhua X, Tanner M, Singer BH (2003) Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials. Antimicrob Agents Chemother 47: 1487-1495.
4. Fenwick A, Savioli L, Engels D, Bergquist RN, Todd MH (2003) Drugs for the control of parasitic diseases: Current status and development in schistosomiasis. Trends Parasitol 19: 509-515.
5. Cioli D, Pica-Mattoccia L, Archer S (1993) Drug resistance in schistosomes. Parasitol Today 9: 162-166.
6. Vermund SH, Bradley DJ, Ruiz-Tiben E (1983) Survival of Schistosoma mansoni in the human host: Estimates from a community-based prospective study in Puerto Rico. Am J Trop Med Hyg 32: 1040-1048.
7. Meister A, Anderson ME (1983) Glutathione. Ann Rev Biochem 52: 711-760.
8. Townsend DM, Tew KD, Tapiero H (2003) The importance of glutathione in human disease. Biomed Pharmacother 57: 145-155.
9. Gromer S, Urig S, Becker K (2004) The thioredoxin system - From science to clinic. Med Res Rev 24: 40-89.
10. Krauth-Siegel RL, Bauer H, Schirmer RH (2005) Dithiol proteins as guardians of the intracellular redox milieu in parasites: Old and new drug targets in trypanosomes and malaria-causing plasmodia. Angew Chem Int Ed Engl 44: 690-715.
11. Alger HM, Williams DL (2002) The disulfide redox system of Schistosoma mansoni and the importance of a multifunctional enzyme, thioredoxin glutathione reductase. Mol Biochem Parasitol 121: 129-139.
12. Johansson L, Gafvelin G, Arnér ES (2005) Selenocysteine in proteins - Properties and biotechnological use. Biochim Biophys Acta 1726: 1-13.
13. Lewis F (1998) Schistosomiasis. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, editors. Current protocols in immunology. New York: John Wiley & Sons. pp. Suppl. 28: 19.1.1-19.1.28.
14. Arnér ESJ, Sarioglu H, Lottspeich F, Holmgren A, Böck A (1999) High-level expression in Escherichia coli of selenocysteine- containing rat thioredoxin reductase utilizing gene fusions with engineered bacterial-type SECIS elements and co-expression with the selA, selB and selC genes. J Mol Biol 292: 1003-1016.
15. Rengby O, Johansson L, Carlson LA, Serini E, Vlamis-Gardikas A, et al. (2004) Assessment of production conditions for efficient use of Escherichia coli in high-yield heterologous recombinant selenoprotein synthesis. Appl Environ Microbiol 70: 5159-5167.
16. Holmgren A, Björnstedt M (1995) Thioredoxin and thioredoxin reductase. Meth Enzymol 252: 199-208.
17. Arnér ESJ, Holmgren A (2000) Measurement of thioredoxin and thioredoxin reductase. In Maines M, Costa L, Reed D, Sassa S editors. Current protocols in toxicology. New York: John Wiley & Sons. pp. 7.4.1-7.4.14.
18. Alger HM, Sayed AA, Stadecker MJ, Williams DL (2002) Molecular and enzymatic characterisation of Schistosoma mansoni thioredoxin. Int J Parasitol 32: 1285-1292.
19. Carlberg I, Mannervik B (1985) Glutathione reductase. Meth Enzymol 113: 484-490.
20. Holmgren A, Åslund F (1995) Glutaredoxin. Meth Enzymol 252: 283-292.
21. Segel IH (1993) Enzyme kinetics. New York: John Wiley & Sons. 957 p.
22. Wendel A (1980) Glutathione peroxidase. In: Jacoby WB, editor. Enzymatic basis of detoxification. Volume 1. New York: Academic Press. pp. 333-353.
23. Bergmeyer HU, Bernt E (1974) Lactate dehydrogenase. In: Bergmeyer HU, editor. Methods of enzymatic analysis. Volume 2. New York: Academic Press. pp. 574-548.
24. Griffith OW (1980) Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 106: 207-212.
25. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, et al. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 107-112.
26. Sun Q-A, Kirnarsky L, Sherman S, Gladyshev VN (2001) Selenoprotein oxidoreductase with specificity for thioredoxin and glutathione systems. Proc Natl Acad Sci U S A 98: 3673-3678.
27. Worthington DJ, Rosemeyer MA (1974) Human glutathione reductase: Purification of the crystalline enzyme from erythrocytes. Eur J Biochem 48: 167-177.
28. Worthington DJ, Rosemeyer MA (1976) Glutathione reductase from human erythrocytes. Catalytic properties and aggregation. Eur J Biochem 67: 231-238.
29. Gromer S, Arscott LD, Williams CH Jr, Schirmer RH, Becker K (1998) Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem 273: 20096-20101.
30. Rigobello MP, Messori L, Marcon G, Agostina Cinellu M, Bragadin M, et al. (2004) Gold complexes inhibit mitochondrial thioredoxin reductase: Consequences on mitochondrial functions. J Inorg Biochem 98: 1634-1641.
31. Millet R, Urig S, Jacob J, Amtmann E, Moulinoux JP, et al. (2005) Synthesis of 5-nitro-2-furancarbohydrazides and their cis- diamminedichloroplatinum complexes as bitopic and irreversible inhibitors of human thioredoxin reductase. J Med Chem 48: 7024-7039.
32. Witte AB, Anestål K, Jerremalm E, Ehrsson H, Arnér ES (2005) Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med 39: 696-703.
33. Davioud-Charvet E, McLeish MJ, Veine DM, Giegel D, Arscott LD, et al. (2003) Mechanism-based inactivation of thioredoxin reductase from Plasmodium falciparum by Mannich bases. Implication for cytotoxicity. Biochemistry 42: 13319-13330.
34. Lee B, Bauer H, Melchers J, Ruppert T, Rattray L, et al. (2005) Irreversible inhibition of trypanothione reductase by unsaturated Mannich bases: A divinylketone as key intermediate. J Med Chem 48: 7400-7410.
35. Cenas N, Nivinskas H, Anusevicius Z, Sarlauskas J, Lederer F, et al. (2004) Interactions of quinones with thioredoxin reductase: A challenge to the antioxidant role of the mammalian selenoprotein. J Biol Chem 279: 2583-2592.
36. Irmler A, Bechthold E, Davioud-Charvet E, Hofmann V, Réau R, et al. (2002) Disulfide reductases. In: Chapman S, Perham R, Scrutton N, editors. Flavins and flavoproteins. Berlin: Agency for Scientific Publ. pp. 803-815.
37. Salmon-Chemin L, Buisine E, Yardley V, Kohler S, Debreu MA, et al. (2001) 2- and 3-substituted 1,4-naphthoquinone derivatives as subversive substrates of trypanothione reductase and lipoamide dehydrogenase from Trypanosoma cruzi: Synthesis and correlation between redox cycling activities and in vitro cytotoxicity. J Med Chem 15: 548-565.
38. Biot C, Bauer H, Schirmer RH, Davioud-Charvet E (2004) 5-substituted tetrazoles as bioisosteres of carboxylic acids. Bioisosterism and mechanistic studies on glutathione reductase inhibitors as antimalarials. J Med Chem 47: 5972-5983.
39. Davioud-Charvet E, Delarue S, Biot C, Schwobel B, Boehme CC, Mussigbrodt A, Maes L, Sergheraert C, Grellier P, Schirmer RH, Becker K (2001) A prodrug form of a Plasmodium falciparum glutathione reductase inhibitor conjugated with a 4-anilinoquinoline. J Med Chem 44: 4268-4276.
40. Vennerstrom JL, Makler MT, Angerhofer CK, Williams JA (1995) Antimalarial dyes revisited: Xanthenes, azines, oxazines and thiazines. Antimicrob Agents Chemother 39: 2671-2677.
41. Schönleben-Janas A, Kirsh P, Mittl PRE, Schirmer RH, Krauth-Siegel RL (1996) Inhibition of human glutathione reductase by 10-arylisoalloxazines: Crystallographic, kinetic, and electrochemical studies. J Med Chem 39: 1549-1554.
42. Archer S (1985) The chemotherapy of schistosomiasis. Ann Rev Pharmacol Toxicol 25: 485-508.
43. Standen OD (1963) Chemotherapy of helminthic infections. In: Schnitzer RJ, Hawking F, editors. Experimental chemotherapy. Volume 1. New York: Academic Press. pp. 701-881.
44. Kitz R, Wilson IB (1962) Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 237: 3245-3249.
45. Bauer H, Fritz-Wolf K, Winzer A, Kühner S, Little S, et al. (2006) A fluoro analogue of the menadione derivative 6-[2′-(3′-methyl)- 1′,4′-naphthoquinolyl] hexanoic acid is a suicide substrate of glutathione reductase. Crystal structure of the alkylated human enzyme. J Am Chem Soc 128: 10784-10794.
46. Markiewicz VR, Saunders LZ, Geus RJ, Payne BJ, Hook JB (1988) Carcinogenicity study of auranofin, an orally administered gold compound, in mice. Fundam Appl Toxicol 11: 277-284.
47. LoVerde PT (1998) Do antioxidants play a role in schistosome host-parasite interactions? Parasitol Today 14: 284-289.
48. Sun QA, Su D, Novoselov SV, Carlson BA, Hatfield DL, et al. (2005) Reaction mechanism and regulation of mammalian thioredoxin/glutathione reductase. Biochemistry 44: 14528-14537.
49. May JM, Mendiratta S, Hill KE, Burk RF (1997) Reduction of dehydroascorbate to ascorbate by the selenoenzyme thioredoxin reductase. J Biol Chem 272: 22607-22610.
50. Xia L, Nordman T, Olsson JM, Damdimopoulos A, Bjorkhem-Bergman L, et al. (2003) The mammalian cytosolic selenoenzyme thioredoxin reductase reduces ubiquinone. A novel mechanism for defense against oxidative stress. J Biol Chem 278: 2141-2146.
51. Su D, Novoselov SV, Sun QA, Moustafa ME, Zhou Y, et al. (2005) Mammalian selenoprotein thioredoxin-glutathione reductase. Roles in disulfide bond formation and sperm maturation. J Biol Chem 280: 26491-26498.
52. Gasdaska PY, Gasdaska JR, Cochran S, Powis G (1995) Cloning and sequencing of a human thioredoxin reductase. FEBS Lett 373: 5-9.
53. Miranda-Vizuete A, Damdimopoulos AE, Pedrajas JR, Gustafsson JA, Spyrou G (1999) The mitochondrial thioredoxin system. Eur J Biochem 261: 405-412.
54. Outten CE, Culotta VC (2004) Alternative start sites in the Saccharomyces cerevisiae GLR1 gene are responsible for mitochondrial and cytosolic isoforms of glutathione reductase. J Biol Chem 279: 7785-7791.
55. Salinas G, Selkirk ME, Chalar C, Maizels RM, Fernandez C (2004) Linked thioredoxin-glutathione systems in platyhelminths. Trends Parasitol 20: 340-346.
56. Davis A (1986) Recent advances in schistosomiasis Q J Med 58: 95-110.
57. Bueding E, Dolan P, Leroy JP (1982) The antischistosomal activity of oltipraz. Res Comm Chem Path Pharmacol 37: 293-303.
58. Moreau N, Martens T, Fleury MB, Leroy JP (1990) Metabolism of oltipraz and glutathione reductase inhibition. Biochem Pharmacol 40: 1299-1305.
59. Fleury MB, Largeron M, Martens T (1991) Toward an understanding of the schistosomicidal effect of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (oltipraz). Biochem Pharmacol 41: 361-367.
60. Carey KA, Kensler TW, Fishbein JC (2001) Kinetic constraints for the thiolysis of 4-methyl-5-(pyrazin-2-yl)-1,2-dithiole-3-thione (oltipraz) and related dithiole-3-thiones in aqueous solution. Chem Res Toxicol 14: 939-945.
61. Navamal M, McGrath C, Stewart J, Blans P, Villamena F, et al. (2002) Thiolytic chemistry of alternative precursors to the major metabolite of the cancer chemopreventive oltipraz. J Org Chem 67: 9406-9413.
62. Velayutham M, Villamena FA, Navamal M, Fishbein JC, Zweier JL (2005) Glutathione-mediated formation of oxygen free radicals by the major metabolite of oltipraz. Chem Res Toxicol 18: 970-975.
63. Christopherson JB (1918) The successful use of antimony in bilharziosis. Br Med J ii: 325-327.
64. Mansour TE, Bueding E (1954) The actions of antimonials on glycolytic enzymes of Schistosoma mansoni. Brit J Pharmacol 9: 459-462.
65. Su J-GJ, Mansour JM, Mansour TE (1996) Purification, kinetics and inhibition by antimonials of recombinant phosphofructokinase from Schistosoma mansoni. Mol Biochem Parasitol 81: 171-178.
66. Kean WF, Hart L, Buchanan WW (1997) Auranofin. Br J Rheumatol 36: 560-572.
67. Maiorino M, Roche C, Kiess M, Koenig K, Gawlik DA, et al. (1996) Selenium-containing phospholipids hydroperoxide glutathione peroxidase in Schistosoma mansoni. Eur J Biochem 238: 838-844.
68. Yamashita M, Ohuchi K, Takayanagi M (2003) Effects of chrisotherapeutic gold compounds on prostaglandin E2 production. Curr Drug Targets - Inflamm Allergy 2: 216-223.
69. Xiao SH, Catto BA, Webster LT Jr (1985) Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo. J Infect Dis 151: 1130-1137.
70. Sabah AA, Fletcher C, Webbe G, Doenhoff MJ (1986) Schistosoma mansoni: Chemotherapy of infections of different ages. Exp Parasitol 61: 294-303.
71. Xiao SH, Chollet J, Weiss NA, Bergquist RN, Tanner M (2000) Preventive effect of artemether in experimental animals infected with Schistosoma mansoni. Parasitol Int 49: 19-24.
72. Anestål K, Arnér ES (2003) Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine. J Biol Chem 278: 15966-15972.